Medical Affairs Plans: From Strategic Planning to Measuring Impact — Episode 3
Listeners will understand how the Medical Affairs strategic planning process can drive decision making throughout the year.
Listeners will understand how the Medical Affairs strategic planning process can drive decision making throughout the year.
Participants will learn the functions and activities of key internal partners and will identify potential areas for compliant collaboration with these partners.
Medical Affairs thought leaders discuss the Pre-21st Century Cures Act uses of Real World Evidence (RWE) in regulatory decision-making.
The Series Podcast Objectives are:
Podcast objectives include understanding how the medical affairs strategic planning process can drive decision making throughout the year
Medical Affairs thought leaders discuss the function, activities and opportunities for compliant collaboration with key internal partners.
Cerise James, MD, moderates this podcast in which Neil Belson, JD, discusses Real World Evidence and its impact to the biopharmaceutical industry.
This Medical Affairs Professional Society (MAPS) podcast features medical affairs thought leaders offering insights into the Medical Affairs strategic planning process
Eileen Sawyer, VP, Global Medical Affairs at uniQure, describes the importance of Medical Affairs acting as a strategic partner, how to effectively engage patients throughout the drug development process, and to ultimately achieve better patient outcomes.
Ralph Rewers, Sr Director, Global Field Medical Excellence at AbbVie, shares how Field Medical professionals are in a position to impact thousands of patients. Dr. Rewers encourages Field Medical professionals to step into the shoes of the individuals they’re speaking with to better understand their beliefs and behaviors, so organizations can better tailor medical communications to how they receive scientific data.
This podcast series discusses the basics of EUMDR, what this means more globally (FDA, CFDA) and finally – how we can view this as the golden opportunity to elevate the science of our products and communicate a compelling medical value proposition.
